Skip to content
AnalystLens

Merck 8-K Report, Financial Results (Feb 3, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed February 3, 2026
Period End
February 3, 2026
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Nov ’24Nov ’24

Summary

Summary of the 8-K filed February 3, 2026. Cited figures are marked; the original filing is the authoritative source.

Merck & Co. (MRK) reported fourth-quarter and full-year 2025 results on February 3, 2026.

Fourth-quarter worldwide sales were $16.4 billiona, up 5% (4% ex-FX), while full-year sales were $65.0 billion, up 1% (2% ex-FX). Growth was led by KEYTRUDA/KEYTRUDA QLEX ($31.7 billion, up 7%) and newer launches including WINREVAIR ($1.4 billion, up from $419 million) and CAPVAXIVE ($759 million). These gains were offset by a 39% decline in GARDASIL/GARDASIL 9 to $5.2 billion, driven by lower China demand and Japan's catch-up program.

Animal Health grew 8% to $6.4 billionb. Full-year non-GAAP EPS was $8.98 (up 17%) and GAAP EPS was $7.28 (up 8%), with the GAAP figure absorbing a $0.20 per-share charge for business development deals. The more consequential news for investors is the 2026 outlook.

Merck guided to sales of $65.5 to $67.0 billionc and non-GAAP EPS of $5.00 to $5.15. That EPS guide is sharply lower than 2025 because it includes a one-time charge of roughly $3.65 per share (about $9.0 billion) tied to the acquisition of Cidara Therapeutics, plus about $0.30 per share of related financing and operating costs. Excluding the Cidara charge, the implied underlying earnings trajectory is considerably more stable.

The outlook also assumes no additional significant business development transactions, which is consistent with Merck's past practice. Management highlighted pipeline progress, including 18 positive Phase 3 readouts in 2025, FDA Commissioner's National Priority Vouchers for enlicitide and sac-TMT, and a U.S. government agreement that delays Section 232 tariffs for three years in exchange for more than $70 billiond in committed U.S. capital and R&D spending.

Key risks for investors are the continued erosion of GARDASIL, KEYTRUDA's dependence on its ongoing lifecycle and the timing of its loss of exclusivity, the rising interest expense and FX losses that pushed other expense higher, and the execution risk of integrating Verona Pharma and Cidara. Because this filing furnishes the press release under Item 2.02, the content is not deemed filed under Section 18 of the Exchange Act.

Key Highlights

  1. Q4 2025 sales rose 5% to $16.4 billion (4% ex-FX); full-year 2025 sales rose 1% to $65.0 billion (2% ex-FX).
  2. KEYTRUDA/KEYTRUDA QLEX full-year sales reached $31.7 billion, up 7%, with KEYTRUDA QLEX contributing $40 million in its first partial year.
  3. GARDASIL/GARDASIL 9 sales fell 39% to $5.2 billion in 2025, reflecting lower China demand and Japan's catch-up immunization program.
  4. New launches are scaling: WINREVAIR reached $1.4 billion (vs. $419 million in 2024) and CAPVAXIVE reached $759 million (vs. $97 million).
  5. Full-year 2025 non-GAAP EPS was $8.98 (up 17%) and GAAP EPS was $7.28 (up 8%), including a $0.20 per-share business development charge.
  6. 2026 guidance calls for sales of $65.5 to $67.0 billion and non-GAAP EPS of $5.00 to $5.15, which includes a one-time Cidara acquisition charge of about $3.65 per share.
  7. Gross margin is guided to about 82% on a non-GAAP basis for 2026, and the outlook excludes any additional significant business development deals.

Frequently Asked Questions

  1. Why is Merck's 2026 EPS guidance so much lower than its 2025 results?

    The 2026 non-GAAP EPS range of $5.00 to $5.15 includes a one-time charge of approximately $9.0 billion, or about $3.65 per share, for the acquisition of Cidara Therapeutics, plus about $0.30 per share of related financing and operational costs. Excluding these items, the underlying earnings base is considerably higher, so investors should look at the adjusted figures to assess operating trends.

  2. What is driving the decline in GARDASIL sales, and how material is it?

    GARDASIL/GARDASIL 9 sales fell 39% to $5.2 billion in 2025, down from $8.6 billion in 2024. The decline reflects sharply lower demand in China, where sales were zero in the second half of 2025, and lower sales in Japan after its national catch-up immunization program. This is a significant headwind to the vaccines franchise and to overall growth.

  3. How is KEYTRUDA performing, and what is its role in the outlook?

    KEYTRUDA/KEYTRUDA QLEX generated $31.7 billion in 2025, up 7%, and accounts for roughly half of total sales. Growth came from earlier-stage indications such as triple-negative breast cancer and non-small cell lung cancer. KEYTRUDA's trajectory is central to Merck's 2026 sales guidance, and investors should monitor its long-term lifecycle as it approaches later patent expiry.

  4. Does the outlook include future acquisitions or licensing deals?

    No. The guidance explicitly does not assume additional significant business development transactions, consistent with Merck's past practice. Any future deals would therefore represent potential upside to sales or cost-related downside, depending on their size and accounting treatment, and could affect the EPS range.